GlassScriptPhysician profile
Julia Harris
NPI 1962828202
$5,027.88
in general payments reported to CMS, 2019-2025
34 companies · $402 in 2025
The $402 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $823 · 2022: $2,274 · 2023: $1,320 · 2024: $208 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,931.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,930.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $671.21 | 2021-2025 | Ozempic, Wegovy |
| Abbvie INC. | $468.91 | 2021-2023 | |
| Amgen INC. | $452.54 | 2021-2024 | Repatha, Otezla |
| Corcept Therapeutics | $365.43 | 2021-2024 | Korlym |
| Mylan Specialty L.P. | $321.16 | 2021-2023 | Yupelri, Yupelri |
| Astrazeneca Pharmaceuticals LP | $303.17 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $289.35 | 2021-2023 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $240.48 | 2021-2022 | |
| Glaxosmithkline, LLC. | $188.98 | 2021-2023 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $168.55 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $149.52 | 2022-2023 | Xifaxan |
| Abbott Laboratories | $149.27 | 2021-2023 | Proclaim |
| Teva Pharmaceuticals USA, INC. | $112.34 | 2025 | Austedo Xr |
| Antares Pharma, INC. | $105.09 | 2023 | Xyosted, Tlando |
| Mannkind Corporation | $104.84 | 2022-2023 | Afrezza |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $100.98 | 2021-2022 | |
| Viiv Healthcare Company | $99.03 | 2024 | Apretude |
| Otsuka America Pharmaceutical, INC. | $95.41 | 2022-2023 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $94.31 | 2022-2023 | |
| Neurocrine Biosciences, INC. | $87.62 | 2023 | |
| Amarin Pharma, INC. | $84.47 | 2021-2022 | |
| Penumbra, INC. | $56.02 | 2024 | Indigo System |
| Pfizer INC. | $53.08 | 2022 | |
| Sun Pharmaceutical Industries INC. | $51.96 | 2023 | Ilumya |
| Biohaven Pharmaceutical Holding Company LTD. | $40.46 | 2022 | |
| Medtronic, INC. | $33.19 | 2022 | |
| Janssen Pharmaceuticals, INC | $25.21 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $19.78 | 2022 | |
| Esperion Therapeutics, INC. | $19.73 | 2021 | |
| Astellas Pharma US INC | $18.90 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.96 | 2022 | |
| Shield Therapeutics INC | $14.82 | 2023 | Accrufer |
| Kowa Pharmaceuticals America, INC. | $12.11 | 2022 | |
| Lundbeck LLC | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.